Get in Touch
We welcome inquiries from patients, healthcare professionals, investors, and potential partners.
Contact Information
For general inquiries, partnership opportunities, or any questions regarding our products and pipeline.
Curatis Holding AG / Curatis AG
Weierweg 7
CH-4410 Liestal, Switzerland
Phone: +41 61 927 8777
Fax: +41 61 927 8775
Safety Reporting / Pharmacovigilance
To report an adverse drug event, please use one of the links below or contact us directly at safety@curatis.com
- Unerwünschtes Arzneimittelereignis melden (DE)
- Report Adverse Drug Event (EN)
- Annoncer un événement indésirable médicamenteux (FR)
Emergency Contact
For emergencies or urgent product complaints on weekends and public holidays:
+41 61 927 8778Commercial Partnerships
Curatis is your partner of choice for pharmaceutical products in Switzerland. We offer customised packages for the commercialisation of pharmaceutical products, taking into account the specific needs of the partner company and its product(s).
- —Specialty care drugs, orphan drugs, and antidotes
- —Registration, pricing, and reimbursement services
- —Targeted marketing and sales activities for specialised products
- —Facilitating patient access before full market authorisation
- —State-of-the-art quality and pharmacovigilance know-how
- —Fast operational processes and communication with partners
- —Accommodation and implementation of partner-specific requirements
European Expansion
In line with the company's geographic expansion strategy, Curatis is looking for distribution partnerships for ultra orphan, orphan, and specialty care medicines in Germany, France, Italy, and the UK.
For more information, please contact us at info@curatis.com
Co-Development & Licensing
Curatis maintains co-development partnerships with innovative small and medium-sized biotech and pharmaceutical companies, as well as best-practice contract research and manufacturing organisations.
Curatis is looking for larger pharmaceutical companies for licensing or co-development arrangements for the late-stage clinical development of its pipeline projects.